Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Szeyi Ng
Observed name:
Sze Yi Ng
Institution:
Institute of Cancer Research
Observed institution:
Institute of Cancer Research
ORCID:
0000-0002-7191-709X
Observed ORCID:
0000-0002-7191-709X
OpenAlex ID:
A5102649111
The Lancet Breast Cancer Commission
2024
·
Charlotte E Coles
, Helena Earl
, et al.
·
The Lancet
·
235
PDF
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial
2025
·
Szeyi Ng
, Lucy S. Kilburn
, et al.
·
Radiotherapy and Oncology
·
4
PDF
Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials
2025
·
Szeyi Ng
, Anna M. Kirby
, et al.
·
Radiotherapy and Oncology
·
2
PDF
Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United Kingdom
2025
·
Szeyi Ng
, Lucy S. Kilburn
, et al.
·
BJC Reports
·
1
PDF
Correction to Lancet Oncol 2026; 27: 181–90
2026
·
Charlotte E Coles
, Helena Earl
, et al.
·
The Lancet Oncology
2023 Factors influencing eligibility and recruitment to breast cancer proton beam therapy trials: findings from the PARABLE trial and recruitment substudy
2026
·
Anna M Kirby
, Szeyi Ng
, et al.
·
Radiotherapy and Oncology
Equity in re-access to specialist care and support in breast cancer pathways in England: a realist-informed qualitative study
2026
·
Patrick Kierkegaard
, Bowen Su
, et al.
·
Research Square
PDF
Abstract PS04-04: Adverse effects (AEs) reported via Patient Reported Outcome Measures (PROMs): A longitudinal analysis of the IMPORT HIGH breast radiotherapy trial (CRUK/06/003)
2024
·
Sze Yi Ng
, Indrani Bhattacharya
, et al.
·
Cancer Research
Show more works
View as search
Works count:
8
Citation count:
242
H-index:
2
I10-index:
1
Year
Topic
Type